Back to results
US 7,820,157 B2Granted
Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
AssigneeUniversity of Southern California
InventorsFrederick L. Hall, Erlinda Maria Gordon
Life of this patent
Estimating the term…
Abstract
A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.
Claims3
A retroviral particle, comprising:
- i) a modified retroviral envelope protein wherein the retroviral envelope protein includes a receptor binding region, wherein the receptor binding region is modified to include a collagen binding domain, and
- ii) at least one desired transgene operably linked to a promoter, wherein the retroviral particle, when delivered to a mammal having a site of tissue injury, binds to collagen exposed at the site of tissue injury, and expresses the desired transgene at the site of tissue injury and wherein the titer of the retroviral particle is at least 1×104 cfu/ml.
A retroviral particle, comprising:
- i) a modified retroviral envelope protein wherein the retroviral envelope protein includes a receptor binding region, wherein the receptor binding region is modified to include a collagen binding domain, and
- ii) at least one desired transgene operably linked to a promoter, wherein the retroviral particle, when delivered to a mammal having a site of tissue injury, binds to collagen exposed at the site of tissue injury, and expresses the desired transgene at the site of tissue injury and wherein the transgene expresses a therapeutic agent.
Dependencies are inferred from the claim text.